Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced the appointment of Aaron Sato, Ph.D., to the newly created position of Chief Strategy Officer. Dr. Sato will be responsible for guiding marketing strategies and engaging with potential partners across a variety of therapeutic approaches, including Adimab’s technology related to monoclonal and multispecific antibody discovery and optimization, T-cell engagers, TCRs, GPCRs and other membrane-obligate targets, as well as other existing and new technology offerings. In addition, Dr. Sato will help lead internal cross-functional efforts to develop competitive intelligence, perform internal and external technology analysis, and drive external technical engagement with drug development companies, key opinion leaders, and industry leaders.
“We are expanding into a growing number of business areas that we are excited about, so we feel that now is the right time to hire additional talent. And it is not often that we have the chance to bring on someone of Aaron Sato’s caliber and experience,” said Philip T. Chase, Chief Executive Officer of Adimab. “Aaron’s significant technical knowledge as well as his deep business development capabilities complement our leadership team perfectly which is why we have chosen to make him our first c-level hire in over 12 years. We are looking forward to everything that Aaron can bring to the team.”
Also Read: Myriad Genetics and Flatiron Health Partner to Make Genetic Testing
“Adimab has been the undisputed industry leader for well over a decade and the breadth and depth of their technology and expertise is unparalleled,” said Dr. Sato. “I am thrilled to join them and in particular, I am excited to help find more opportunities for this amazing group of scientists to collaborate with drug developers all over the world.”
About Aaron Sato
Aaron comes to Adimab with over 25 years of experience in biotechnology, focusing on discovering and developing novel first-in-class antibody therapeutics. Before joining Adimab, Aaron served as the Chief Scientific Officer of Twist Bioscience, where he led their Biopharma Solutions business. Prior to Twist, he was the Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovered novel antibody therapeutics for its clients. He also oversaw all discovery research functions as Vice President of Protein Sciences at Surrozen and previously as Vice President of Research at Sutro Biopharma, Inc. Additionally, he held director-level positions at both Oncomed and Dyax Corp. Aaron earned his Ph.D. in Chemistry from the Massachusetts Institute of Technology, where he studied MHC class II structure-function relationships. He is the author of over 40 peer-reviewed papers and 60 issued patents in the antibody space.
SOURCE: Businesswire